Publications in collaboration with researchers from Complexo Hospitalario Universitario de Pontevedra (43)

2024

  1. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine, Vol. 129, pp. 78-86

  2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  3. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis

    Nefrologia

2023

  1. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  2. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

  3. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  2. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  3. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  4. Treat-To-Target in rheumatoid arthritis: A real-world study of the application and impact of treat-To-Target within the wider context of patient management, patient centricity and advanced therapy use in Europe

    RMD Open, Vol. 8, Núm. 2

  5. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. A family-based study to identify genetic biomarkers of fibromyalgia: consideration of patients' subgroups

    Clinical and experimental rheumatology, Vol. 39, Núm. 3, pp. 144-152

  2. Epidemiological Characteristics and Adverse Events of Patients with Psoriatic Arthritis Undergoing Treatment with Biological Therapies in Galicia

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 150-154

  3. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  4. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

  5. Pachydermodactyly: a systematic review

    Irish Journal of Medical Science, Vol. 190, Núm. 3, pp. 1005-1014

  6. Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

    Aging Clinical and Experimental Research, Vol. 33, Núm. 11, pp. 2929-2939

  7. Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 203-206

  8. The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis

    Clinical and experimental rheumatology, Vol. 39, Núm. 2, pp. 21-26

  9. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13